BPS 2017 Proceedings
Meienhofer Keynote Address
Daniel H. Rich
Professor of Medicinal and Organic Chemistry
University of Wisconsin – Madison
Nature’s Peptide Mimetics. Unique Structures. Surprising Properties.
Peptide Showcase
Brief 15 minute presentations from companies developing peptide therapeutics and related technologies. This rapid and compressed format is designed for quick introduction between symposium participants to new technologies, and companies. Each presentation is structured to highlight the value of the technology or therapeutic being offered and the business strategy.
Peter Gengo
Vice President
Renova Therapeutics
Gene and Peptide Therapy for Chronic Diseases
Alex Batchelor
Alex
Orbit Discovery Ltd
ORBIT Peptide Display – High Throughout Selection of Peptides with Biological Function
Victor Hruby
Victor
MCR Therapeutics
Development of Novel Melanotropin Ligands for the Prevention and Treatment of Disease
Ratmir Derda
Ratmir
University of Alberta // 48Hour Discovery, Inc.
48Hour Discovery of Chemically-modified Peptide Ligands
Brandon Chen
Co-Founder
Snap Bio, Inc.
Novel Cyclic Peptides Derived from Nature
Lauren Goodrich
Scientist
Roche Madison
Massively Parallel Synthesis and Screening of Linear Peptides and Macrocycles using Peptide Microarrays
David Bramhill
CEO
EnduRx
Targeted Peptides That Revoke Immune Privilege for Solid Tumor Therapy
Brian Del Buono
Vice President
Stuart Therapeutics
Production and Use of Collagen Mimetic Peptides for Therapeutic and Diagnostic Applications
Research Showcase
Brief 15 minute presentations of applied research from the academic labs.
Len Luyt
Len
University of Western Ontario
Fluorinated peptides and peptidomimetics targeting the ghrelin receptor (GHSR-1a)
Kimberly Kelly
Co-Founder and Partner
Blue Ridge Biosciences
The Role of Molecularly Targeted Affinity Ligands in our Understanding of Human Disease, Pharmaceutical Discovery and Development, Nanotechnology Sensing Applications, Systems Biology, and the Design of Molecular Imaging Agents.
Mathieu Cinier
Scientific Director
Affilogic
Oral Administration of Nanofitins: Hyperstable Small Affinity Proteins
Pierre Bernard-Savary
President
Intl Symposium for HPTLC / Club de CCM / Chromacim
EVERY ANALYST MUST KNOW HPTLC, TO CHOOSE THE MOST ADAPTED METHOD FOR ANY SAMPLE NEED, OR JUST TO SQUARE THE CIRCLE.
Peptides in the Clinic
Updates on clinical development of peptide therapeutics.
Natalie Winblade Nairn
Director, Formulation and Peptide Drug Discovery
Blaze Bioscience
Tozuleristide, a knottin-fluorophore clinical candidate for real-time detection and visualization of tumor and tumor margins during resection surgery
Dave Garman
Chief Technology Officer
NoNO Inc.
FRONTIER and ESCAPE-NA-1: Two complimentary Phase 3 clinical trials to demonstrate the efficacy of NA-1 in acute ischemic stroke
Hazel Szeto
Scientific Founder
Stealth Biotherapeutics
Discovery and Clinical Development of Elamipretide
Jim Trevaskis
Principal Scientist
MedImmune
MEDI0382, a novel dual GLP1/glucagon receptor agonist, from bench to bedside
Drug Delivery
Novel approaches to peptide drug delivery including devices, molecular engineering, conjugation, and formulation technologies
Joel Richard
Senior Vice President, Peptides
IPSEN
Advances in Non-Invasive Routes of Administration of Peptides: Focus on Successful Oral Technologies Progressing in the Clinic
Uli Binder
Chief Technology Officer
XL-protein GmbH
Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action
Advances in Chemistry
Timo Nuijens
Lead Scientist
EnzyPep
Enzymatic ligation technologies as adjuncts for the assembly of peptides and proteins
Wilfred Van der Donk
Professor of Chemistry
University of Illinois at Urbana-Champaign
Combinatorial Methods Towards Genetically Encoded Cyclic Peptides
Richard Houghten
Founder, CEO
Torrey Pines Institute for Molecular Studies
Search through 10’s of millions of synthetic compounds while requiring the screening of only 300-600 samples!
Kate Carroll
Associate Professor
The Scripps Research Institute – Florida
Cysteine-Mediated Redox Signaling: Chemical Tools for Biology Discovery
Maria Luisa Mangoni
Associate Professor
University of Rome
Derivatives of the Frog-Skin Peptide Esculentin-1a with Promising activity Against Infections Induced by Pseudomonas Aeruginosa
Workshop
Pharm Development Panel discussion
Dave Garman
Chief Technical Officer
NoNo Inc
Panel Discussion: The Virtual Drug Development Model
Daron Evans
Managing Director
PoC Capital, LLC
Panel Discussion: The Virtual Drug Development Model